OXFORD, UK: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announced that its subsidiary Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”), a high-performing full-scope scope AAV manufacturing and innovation business, has signed an agreement with a new undisclosed, U.S. based, private biotechnology company.
The agreement grants the partner access to Oxford Biomedica Solutions’ process and manufacturing platform, and “The Full Solution” service offering, with end-to-end capabilities for their pre-clinical gene therapy programmes.
Under the terms of the agreement, Oxford Biomedica Solutions will receive payments relating to the full scope of process development, from construct design through to toxicology manufacturing for the partner’s programmes.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: “We are delighted to announce this new AAV partnership, and look forward to offering Oxford Biomedica Solutions’ full-scope platform to our new partner and supporting them with their construct design and product development needs. This agreement marks a very important step towards achieving our strategic objective of becoming a global viral vector leader across all key vector types, delivering life changing therapies to patients.”